NEW YORK--(BUSINESS WIRE)--Haymarket Media, Inc. is pleased to announce that it has acquired the American Journal of Endocannabinoid Medicine (AJEM)—a peer-reviewed journal focused on cannabinoid medicine. Haymarket is making an additional investment in AJEM to increase its engagement with healthcare professionals (HCPs) and fulfill its mission to educate and inform the medical community on cannabinoid-based therapy.
Physicians are not trained in the endocannabinoid system (ECS) in medical school. Yet, they are increasingly tasked with caring for patients using cannabinoid-based medicine—often in conjunction with other pharmaceuticals. AJEM fills this knowledge gap and provides the medical community widespread access to high-quality, trusted, peer-reviewed content.
“It was important for us to find the right partner to continue AJEM’s journey,” says Ken Watkins, Brand Director of AJEM. “Haymarket’s healthcare presence allows us to broaden our reach and offer content to physicians in a way that is familiar to them, and in a language that they speak—the language of science. We are committed to publishing the latest peer-reviewed research and medical education on the endocannabinoid system as a therapeutic target,” says Watkins, who founded and launched AJEM in 2019.
“Adding a peer-reviewed medical cannabis journal to our portfolio reinforces our commitment to educating physicians and positions Haymarket for leadership in this emerging therapeutic area,” says Lee Maniscalco, CEO of Haymarket Media, Inc.
AJEM joins the Haymarket Medical Network (HMN) and will benefit from the division’s digital expertise in delivering relevant and timely clinical content to a broad audience of HCPs. “The future of this therapeutic pathway is bright and I am excited that Haymarket will provide clinicians the opportunity to engage with evidence-based research on cannabinoid medicine,” says Mike Graziani, President of Haymarket’s Medical Communications Group.
“I am delighted to be a part of such an intelligent, collaborative effort. Haymarket’s resources will allow us to finally provide much-needed endocannabinoid education to those on the front lines of medicine,” says Leslie Apgar, MD, Editor-in-Chief of AJEM.
For more information or sponsorship opportunities, contact Ken Watkins, Brand Director. For manuscript submissions, contact Meg Block Roloff, MPH, Senior Managing Editor.
About the American Journal of Endocannabinoid Medicine
The American Journal of Endocannabinoid Medicine’s (AJEM) mission is to educate healthcare professionals on medicines that engage with the endocannabinoid system (ECS). By presenting clinical research on the role of the ECS in achieving homeostasis and as a therapeutic target, AJEM seeks to improve the practice of evidence-based cannabinoid medicine. AJEM publishes peer-reviewed original research manuscripts and research interpretation, news, and opinion pieces from thought leaders in the field. AJEM’s renowned Editorial Board members assist in the peer-review process and are a diverse group of experts with experience in various cannabinoid medicine disciplines. To learn more, visit www.ajendomed.com.
About Haymarket Medical Network
Haymarket Medical Network reaches healthcare practitioners through a multichannel environment with more than 20 unique brands offered across multiple formats—web, app, print, and live events. Its interconnectivity allows users to move from brand to brand to discover the relevant content they need to make practice-related decisions. The network includes renowned drug database MPR and an expanding portfolio of websites that deliver valuable content covering specific therapeutic areas such as Cardiology Advisor, Neurology Advisor, Infectious Disease Advisor and Cancer Therapy Advisor. To learn more, visit www.haymarketmedicalnetwork.com.
